Show Summary Details
You do not have access to this content

US Supreme Court decision on reverse payment agreements: new era in patent litigation settlements – FTC v Actavis, Inc., 570 US (2013)

Olga Gurgula

Keywords: Actavis; antitrust; drugs; patents; pharmaceutical; reverse payment agreements

Reverse payment agreements have long been the cause of sharp debate between pharmaceutical industry stakeholders as regards this fundamental question: what is more important within the context of Hatch-Waxman patent settlements – patent law or competition law? As with the question, ‘what came first, the chicken or the egg?’, US courts also seem to struggle to answer this question. However, the US Supreme Court has finally considered the issue and has given guidance to the lower courts. It held that these type of agreements are not immune from antitrust scrutiny and firmly rejected the settled ‘scope of patent’ approach largely used by the courts, as well as the FTC’s ‘quick look’ test, suggesting that reverse payment agreements must be analysed under the antitrust ‘rule of reason’ approach.

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information

or login to access all content.